LTG-305
/ Latigo Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 26, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Latigo Biotherapeutics | N=80 ➔ 120
Enrollment change
November 20, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Latigo Biotherapeutics | Not yet recruiting ➔ Recruiting
Enrollment open
August 15, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=80 | Not yet recruiting | Sponsor: Latigo Biotherapeutics
New P1 trial
1 to 3
Of
3
Go to page
1